Prostate Cancer Market Report 2017: Global Epidemiology Forecast to 2026
Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.1 million men were diagnosed with prostate cancer in 2012. Diagnosed incident cases of prostate cancer is def
(EMAILWIRE.COM, April 05, 2018 ) In 2016, there were 470,099 diagnosed incident cases of prostate cancer in the 7MM. The US had the most cases with 153,623, or 32.68% of cases in the 7MM, followed by Japan (104,389, 22.21% of cases). The number of cases in the 7MM is expected to grow to 548,394 in 2026, for an Annual Growth Rate (AGR) of 1.67%. In 2016, there were 4,452,307 prevalent cases of prostate cancer diagnosed in the previous 10 years in the 7MM. The US made up the largest share of prevalent cases with 1,872,922, or 42.07% of cases in the 7MM. Japan had the next highest number of cases with 698,512, followed by Germany with 542,521. The number of 10-year prevalent cases in the 7MM is expected to increase to 4,634,443 by 2026, for an AGR of 0.41% per year.
Report Source: https://www.themarketreports.com/report/epicast-report-prostate-cancer-epidemiology-forecast-to-2026
Scope
• The Prostate Cancer EpiCast Report provides an overview of the risk factors and global trends for prostate cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 35 years), stage at diagnosis (stage I, II, III, and IV), and risk of biochemical recurrence (low, intermediate, and high) in these markets. Additionally, this report forecasts 10-year prevalent cases of prostate cancer segmented by castration resistance, metastases, and HRD mutations.
• The Prostate Cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Purchase this report at: https://www.themarketreports.com/report/buy-now/938431
Reasons To Buy
• Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
• Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
• Understand magnitude of prostate cancer population by risk of biochemical recurrence, castration resistance, metastasis, and HRD mutations.
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/938431
Report Source: https://www.themarketreports.com/report/epicast-report-prostate-cancer-epidemiology-forecast-to-2026
Scope
• The Prostate Cancer EpiCast Report provides an overview of the risk factors and global trends for prostate cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 35 years), stage at diagnosis (stage I, II, III, and IV), and risk of biochemical recurrence (low, intermediate, and high) in these markets. Additionally, this report forecasts 10-year prevalent cases of prostate cancer segmented by castration resistance, metastases, and HRD mutations.
• The Prostate Cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Purchase this report at: https://www.themarketreports.com/report/buy-now/938431
Reasons To Buy
• Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
• Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
• Understand magnitude of prostate cancer population by risk of biochemical recurrence, castration resistance, metastasis, and HRD mutations.
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/938431
Contact Information:
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results